| |
| Press Release: Abnova & Olink promote unique target specific assays for cell signaling studies |
| 2009/04/16 |
|
For immediate release
Media Contact: Ashley Ho
+886-287511888 Ext. 130
pr@abnova.com
www.abnova.com
Abnova and Olink co-marketing agreement
to promote unique target specific assays for cell signaling studies
Neihu, Taiwan and Uppsala, Sweden (April 16, 2009).
Abnova Corporation and Olink Bioscience today announce a co-development and co-marketing
agreement. This collaboration will address the unmet need for high performance assays for studies of
protein phosphorylation and protein interactions by combining Abnova's growing collection of +30,000
antibodies with the DuolinkR product line from Olink Bioscience. Hundreds of target specific assays will
jointly be marketed by the two companies, while sales of the proprietary products will be handled by the
respective companies and their distributors.
The Duolink product line is based on in situ PLATM, a proximity ligation assay technology which combines
dual recognition of the analyte with a DNA amplification based reporter system, resulting in unparalleled
specificity and sensitivity for in situ detection of proteins, protein interactions and protein modifications.
It enables detection of single molecular events in fixed cells and tissue and has found widespread use in
the study of signal transduction and drug mechanism of action.
Having established a strong presence as the world's largest manufacturer of quality antibody reagents,
Abnova embarks on the next mission to apply its capability and antibody portfolio to the protein quanti-
fication arena. "Olink has developed a powerful technology which bridges the need to study both the
qualitative and quantitative aspect of proteins," stated Wilber Huang, President and CEO of Abnova.
"Development of matched antibody pair for ELISA assays marked our first entry into the quantitative
market. This collaboration with Olink Bioscience provides a great opportunity to elevate the applications
of immunofluorescence and immunohistochemistry to the molecular level with unprecedented specificity
and sensitivity of protein detection and quantification."
"We are very pleased to enter into this non-exclusive collaboration with Abnova, one of the largest
antibody providers on the market. It is an important step in our effort to add content to our unique Duolink
detection platform by collaborating with a premier supplier of antibodies. This will enable us to provide our
customers with convenient and demonstrated assays for defined targets. Furthermore, the collaboration
illustrates that Duolink is becoming a standard for high performance in situ studies of proteins, protein
interactions and protein modification," says Bjorn Ekstrom, CEO of Olink Bioscience.
The first co-marketing activities will take place at the 100th Annual Meeting of American Association of
Cancer Research, which will take place at the Colorado Convention Centre, Denver, Colorado, USA on
April 18-22, 2009. The two companies will cross-refer to each other's products, Olink Bioscience will be
found at booth #825 and Abnova at booth #2160.
----------------------------------------------------------------------------------------------------------------------------------------------------
Company information
Abnova is a bio-tool proteomic company specializing in high throughput protein expression and antibody
production. The system Abnova has developed is a unique combination of world-class technologies and
management experience of the IT industry in Taiwan. The company's goal is to vastly expand the scope and availability of bio-tool reagents. As such, it is a taking a genome-wide approach to the production of human recombinant protein and antibody, and is developing a portfolio of integrated and systemized applications including immuno- and multiplex assays covering protein families that are essential to the drug discovery and diagnostic industries.
Olink AB is a privately held biotech supply company based in Uppsala, Sweden founded in 2004. The company controls significant IP covering technologies related to detection and analysis of proteins and nucleic acids. In 2007, Olink introduced the Duolink products for in situ detection of proteins, protein interactions and protein modifications. These PLA, proximity ligation assay, products use dual recognition of the analyte, in combination with a DNA amplification based reporter system, which results in unparalleled sensitivity and specificity. Duolink products enable detection of single molecular events in fixed cells and tissue. Duolink is available as reagent kits and Contract Research projects through Olink Bioscience. www.olink.com
|
 |
| |
|
